Howard M. Fillit

Q: What Schools Are Affiliated With Howard M. Fillit

Howard M. Fillit is affiliated with the following schools: Icahn School of Medicine at Mount Sinai, Rockefeller University, University of Pittsburgh

Howard M. Fillit's AcademicInfluence.com Rankings

Howard M. Fillit

Philosophy

#7811

World Rank

#11069

Historical Rank

Logic

#4848

World Rank

#6177

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Howard M. Fillit's Degrees

Masters Neurobiology and Behavior Columbia University

Why Is Howard M. Fillit Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Howard M. Fillit's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. (1990) (2616)
Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. (2004) (1207)
A call for transparent reporting to optimize the predictive value of preclinical research (2012) (1036)
Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis (2016) (716)
Elevated circulating tumor necrosis factor levels in Alzheimer's disease (1991) (494)
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019 (2022) (445)
Observations in a preliminary open trial of estradiol therapy for senile dementia-alzheimer's type (1986) (374)
Achieving and maintaining cognitive vitality with aging. (2002) (306)
Improving dementia care: The role of screening and detection of cognitive impairment (2013) (227)
Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders (1994) (223)
Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study (2018) (204)
Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology (2016) (201)
Cardiovascular risk factors and dementia. (2008) (200)
Biomarkers of aging: from primitive organisms to humans. (2004) (188)
Alzheimer’s disease and related dementias increase costs of comorbidities in managed Medicare (2002) (185)
Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE (2015) (161)
Cost of Alzheimer's Disease and Related Dementia in Managed‐Medicare (1999) (153)
Developing novel blood-based biomarkers for Alzheimer's disease (2014) (146)
The Vascular Impairment of Cognition Classification Consensus Study (2017) (140)
Predicting Alzheimer’s disease progression using multi-modal deep learning approach (2019) (136)
The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis (1994) (134)
The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease (2020) (133)
The Frailty Identity Crisis (2009) (125)
Recommendations for best practices in the treatment of Alzheimer's disease in managed care. (2006) (111)
Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies (2011) (111)
Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes [see comments] (1994) (110)
Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer’s disease and related disorders (2012) (109)
Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease (2007) (101)
Heparin Oligosaccharides that Pass the Blood‐Brain Barrier Inhibit β‐Amyloid Precursor Protein Secretion and Heparin Binding to β‐Amyloid Peptide (1998) (98)
Cardiovascular disease risk factors and cognitive impairment. (2006) (94)
Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy. (2002) (93)
Should older adults be screened for dementia? It is important to screen for evidence of dementia! (2007) (92)
Alzheimer's Disease–Related Dementias Summit 2016: National research priorities (2017) (91)
Binding of secreted human neuroblastoma proteoglycans to the Alzheimer's amyloid A4 peptide (1993) (88)
The role of hormone replacement therapy in the prevention of Alzheimer disease. (2002) (87)
Optimizing Coding and Reimbursement to Improve Management of Alzheimer's Disease and Related Dementias (2002) (86)
Estrogens in the Pathogenesis and Treatment of Alzheimer's Disease in Postmenopausal Women (1994) (84)
Polypharmacy management in Medicare managed care: changes in prescribing by primary care physicians resulting from a program promoting medication reviews. (1999) (83)
The pharmacoeconomics of Alzheimer's disease. (2000) (79)
Antibodies to basement membrane collagen and to laminin are present in sera from patients with poststreptococcal glomerulonephritis (1986) (76)
Apolipoprotein E‐derived peptides reduce CNS inflammation: implications for therapy of neurological disease (2006) (75)
IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders (2009) (75)
Non-coding variability at the APOE locus contributes to the Alzheimer’s risk (2019) (74)
Translating the biology of aging into novel therapeutics for Alzheimer disease (2018) (72)
Medicare Expenditures of Individuals with Alzheimer's Disease and Related Dementias or Mild Cognitive Impairment Before and After Diagnosis (2016) (71)
Binding of heparan sulfate glycosaminoglycan to β‐amyloid peptide: inhibition by potentially therapeutic polysulfated compounds (1994) (71)
Binding of vascular heparan sulfate proteoglycan to Alzheimer's amyloid precursor protein is mediated in part by the N-terminal region of A4 peptide (1993) (69)
Expert consensus document: Mind the gaps—advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions (2015) (69)
Antivascular antibodies in the sera of patients with senile dementia of the Alzheimer's type. (1987) (69)
Functional Impairment, Healthcare Costs and the Prevalence of Institutionalisation in Patients with Alzheimer’s Disease and Other Dementias (2012) (68)
From bedside to bench: does mental and physical activity promote cognitive vitality in late life? (2006) (68)
The Effect of Dementia on Acute Care in a Geriatric Medical Unit (1992) (67)
2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease (2014) (65)
Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. (1994) (65)
Current evidence for the clinical use of long-chain polyunsaturated N-3 fatty acids to prevent age-related cognitive decline and Alzheimer’s disease (2013) (64)
Immunohistochemical identification of thrombospondin in normal human brain and in Alzheimer's disease. (1992) (64)
Sera from patients with poststreptococcal glomerulonephritis contain antibodies to glomerular heparan sulfate proteoglycan (1985) (64)
Dependence as a unifying construct in defining Alzheimer's disease severity (2010) (62)
Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development (2013) (62)
A Prospective Study of the Effect of Hypertension and Baseline Blood Pressure on Cognitive Decline and Dementia in Postmenopausal Women: The Women's Health Initiative Memory Study (2008) (61)
Economics of dementia and pharmacoeconomics of dementia therapy. (2005) (60)
Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology (2020) (56)
Patterns of healthcare utilization and costs for vascular dementia in a community-dwelling population. (2005) (54)
Practicality of a computerized system for cognitive assessment in the elderly (2008) (53)
Serial studies on circulating immune complexes in post-streptococcal sequelae. (1978) (52)
The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory (2019) (52)
Impact of Donepezil on Caregiving Burden for Patients With Alzheimer's Disease (2000) (52)
Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer’s Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data (2017) (51)
The costs of vascular dementia A comparison with Alzheimer's disease (2002) (51)
Renal Disease in the Geriatric Patient (1984) (50)
Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer’s disease (2014) (50)
House calls: a practical guide to seeing the patient at home. (1995) (50)
A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium (2008) (50)
Cellular reactivity to altered glomerular basement membrane in glomerulonephritis. (1978) (49)
The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier) (2013) (49)
Thiobarbituric acid reactive material in uremic blood. (1981) (48)
Decisions for and against resuscitation in an acute geriatric medicine unit serving the frail elderly. (1992) (46)
Methodological issues in primary prevention trials for neurodegenerative dementia. (2009) (44)
Aducanumab and the FDA — where are we now? (2021) (44)
Autoantibodies to vascular heparan sulfate proteoglycan in systemic lupus erythematosus react with endothelial cells and inhibit the formation of thrombin-antithrombin III complexes. (1994) (43)
The role of anthropometry in the assessment of malnutrition in the hospitalized frail elderly. (1993) (43)
Overcoming obstacles to repurposing for neurodegenerative disease (2014) (42)
Cellular immunity in glomerulonephritis. (1982) (41)
Findings from the National Memory Screening Day Program (2015) (40)
Hospitalizations for ambulatory care sensitive conditions and unplanned readmissions among Medicare beneficiaries with Alzheimer's disease (2017) (39)
Alzheimer's disease research and development: a call for a new research roadmap (2014) (39)
The Nonuse of Urethral Catheterization in the Management of Urinary Incontinence in the Teaching Nursing Home (1983) (38)
The effect of donepezil therapy on health costs in a Medicare managed care plan. (2002) (38)
Usefulness of the Neurobehavioral Cognitive Status Examination in the Hospitalized Elderly (1992) (38)
Heparin oligosaccharides that pass the blood-brain barrier inhibit beta-amyloid precursor protein secretion and heparin binding to beta-amyloid peptide. (1998) (38)
Monoclonal antibodies to heparan sulfate proteoglycan: development and application to the study of normal tissue and pathologic human kidney biopsies. (1988) (38)
Autoantibodies to the protein core of vascular basement membrane heparan sulfate proteoglycan in systemic lupus erythematosus. (1993) (38)
Beyond amyloid: the future of therapeutics for Alzheimer's disease. (2012) (36)
Heparin promotes ß-secretase cleavage of the Alzheimer's amyloid precursor protein (1997) (36)
Evaluation of the Neuroprotective Potential of N-Acetylcysteine for Prevention and Treatment of Cognitive Aging and Dementia. (2017) (36)
Induction of antibodies to hyaluronic acid by immunization of rabbits with encapsulated streptococci (1986) (35)
New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures (2019) (35)
Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics (2019) (35)
Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis (2021) (34)
The Quest for Immortality: Science at the Frontiers of Aging (2001) (34)
Large-scale genomics unveil polygenic architecture of human cortical surface area (2015) (34)
Donepezil use in managed Medicare: effect on health care costs and utilization. (1999) (34)
Masculine vitality: pros and cons of testosterone in treating the andropause. (2004) (33)
Dementia diagnosis disparities by race and ethnicity (2020) (32)
Validation of a brief screen for cognitive impairment (BSCI) administered by telephone for use in the medicare population. (2005) (32)
Antibodies to vascular heparan sulfate proteoglycan in patients with systemic lupus erythematosus. (1991) (32)
Older Americans' Risk-benefit Preferences for Modifying the Course of Alzheimer Disease (2009) (31)
Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation (2017) (31)
Regulation of the Heparan Sulfate Proteoglycan, Perlecan, by Injury and Interleukin‐1α (1999) (31)
Specificities of heparin-binding sites from the amino-terminus and type 1 repeats of thrombospondin-1. (2000) (31)
Economic Burden, Mortality, and Institutionalization in Patients Newly Diagnosed with Alzheimer's Disease. (2017) (31)
Alzheimer's Disease Drug Development (2022) (30)
Disorders of the extracellular matrix and the pathogenesis of senile dementia of the Alzheimer's type. (1995) (30)
Optimization of an alcian blue dot-blot assay for the detection of glycosaminoglycans and proteoglycans. (1991) (30)
New directions for frontotemporal dementia drug discovery (2008) (30)
Identification of Alcoholism and Depression in a Geriatric Medicine Outpatient Clinic (1993) (30)
Monoclonal antibodies to heparan sulfate inhibit the formation of thrombin-antithrombin III complexes. (1993) (30)
Brocklehurst's Textbook of Geriatric Medicine and Gerontology Fillit Howard M Rockwood Kenneth and Young John Brocklehurst's Textbook of Geriatric Medicine and Gerontology 1168pp £164.69 Elsevier 9780702061851 0702061859 [Formula: see text]. (2003) (30)
The Economic Benefits of Acetylcholinesterase Inhibitors for Patients with Alzheimer Disease and Associated Dementias (2004) (30)
Barriers to drug discovery and development for Alzheimer disease. (2002) (28)
Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits (2016) (28)
Immunogenicity of liposome-bound hyaluronate in mice. At least two different antigenic sites on hyaluronate are identified by mouse monoclonal antibodies (1988) (27)
Unintended benefits: the potential economic impact of addressing risk factors to prevent Alzheimer's disease. (2014) (27)
Evidence for the presence of antibodies to cholinergic neurons in the serum of patients with Alzheimer's disease (1987) (26)
Identification of antigenic epitopes in type IV collagen by use of synthetic peptides. (1993) (25)
Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study. (2005) (24)
Costs of Early Stage Alzheimer’s Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)1 (2020) (23)
Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis (2019) (22)
Cognitive decline : strategies for prevention (1997) (21)
AIDS in the elderly: a case and its implications. (1989) (21)
18F-florbetapir Positron Emission Tomography–determined Cerebral &bgr;-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery (2018) (21)
Heparin promotes beta-secretase cleavage of the Alzheimer's amyloid precursor protein. (1997) (21)
Probable Heterosexual Transmission of AIDS in an Aged Woman (1992) (20)
Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer's disease. (2021) (20)
Studies of hospital social stays in the frail elderly and their relationship to the intensity of social work intervention. (1993) (20)
Accelerating Alzheimer's disease drug innovations from the research pipeline to patients (2018) (20)
A Brain Capital Grand Strategy: toward economic reimagination (2020) (20)
A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer’s Disease Patients (2017) (20)
The neurobiology of gonadal hormones and cognitive decline in late life. (1997) (19)
Real-Time Digital Contact Tracing: Development of a System to Control COVID-19 Outbreaks in Nursing Homes and Long-Term Care Facilities (2020) (19)
A Novel Joint Brain Network Analysis Using Longitudinal Alzheimer’s Disease Data (2019) (19)
Translating Current Knowledge Into Dementia Prevention (2012) (19)
Obtaining Informed Consent in the Teaching Nursing Home (1983) (19)
Racial and Ethnic Differences in Knowledge About One's Dementia Status. (2020) (18)
Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer’s disease (2007) (17)
Autoimmunity to cholinergic‐specific antigens of the brain in senile dementia of the Alzheimer's type (1988) (16)
Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease (2021) (15)
Health economics and the value of therapy in Alzheimer’s disease (2007) (14)
Vascular dementia: stroke prevention takes on new urgency. (1993) (14)
Drug discovery for Alzheimer’s disease (2007) (14)
Cytotoxicity to endothelial cells by sera from aged MRL/lpr/lpr mice is associated with autoimmunity to cell surface heparan sulfate. (1995) (14)
Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia (2021) (13)
A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline (2016) (13)
Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force (2019) (13)
Memantine discontinuation and the health status of nursing home residents with Alzheimer's disease. (2010) (13)
Dementia Prevention: optimizing the use of observational data for personal, clinical, and public health decision-making. (2014) (12)
A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer’s disease (2016) (12)
Novel strategies for the prevention of dementia from Alzheimer's disease (2009) (12)
Artificial Intelligence–Powered Digital Health Platform and Wearable Devices Improve Outcomes for Older Adults in Assisted Living Communities: Pilot Intervention Study (2020) (12)
How the principles of geriatric assessment are shaping managed care. (1998) (12)
Use of ineffective or unsafe medications among members of a Medicare HMO compared to individuals in a Medicare fee-for-service program. (1997) (11)
Association of autoimmunity to vascular heparan sulfate proteoglycan and vascular disease in the aged. (1993) (11)
Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer's disease and related disorders (2012) (11)
Challenges for Acute Care Geriatric Inpatient Units Under the Present Medicare Prospective Payment System (1994) (11)
Clinical immunology of aging (1994) (11)
NATIONAL ESTIMATES OF POTENTIALLY AVOIDABLE HOSPITALIZATIONS AMONG MEDICARE BENEFICIARIES WITH ALZHEIMER’S DISEASE AND RELATED DEMENTIAS (2016) (10)
Future Therapeutic Developments of Estrogen Use (1995) (10)
Therapeutics for cognitive aging (2010) (10)
Observation of Patient and Caregiver Burden Associated with Early Alzheimer’s Disease in the United States: Design and Baseline Findings of the GERAS-US Cohort Study1 (2019) (10)
Autoimmune markers in HIV-associated dementia (2003) (10)
Antibodies in Serum of Patients with Alzheimer's Disease Cause Immunolysis of Cholinergic Nerve Terminals from the Rat Cerebral Cortex (1989) (9)
Low flow continuous peritoneal dialysis in acute renal failure. (1981) (9)
Strategies for drug discovery for cognitive aging and alzheimer’s disease (2002) (9)
FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease (2020) (9)
Value-Generating Exploratory Trials in Neurodegenerative Dementias (2021) (8)
A telescope GWAS analysis strategy, based on SNPs-genes-pathways ensamble and on multivariate algorithms, to characterize late onset Alzheimer’s disease (2020) (8)
Proteoglycans and the acute-phase response in Alzheimer's disease brain (1994) (8)
Evidence needs to be translated, whether or not it is complete. (2014) (8)
Intravenous immunoglobulins for Alzheimer's disease (2004) (8)
Advancing drug discovery for Alzheimer's disease. (2005) (7)
Neurogenesis as a therapeutic strategy for cognitive aging and Alzheimer's disease. (2006) (7)
Association of the US Food and Drug Administration Antipsychotic Drug Boxed Warning With Medication Use and Health Outcomes in Elderly Patients With Dementia (2020) (7)
Drug discovery and the prevention of Alzheimer’s disease (2008) (7)
Beyond amyloid: a diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias (2011) (7)
Correlation between Alzheimer’s disease and type 2 diabetes using non-negative matrix factorization (2021) (7)
The effect of a fitness program on health status and health care consumption in Medicare MCOs. (2001) (7)
Meeting the unique challenges of drug discovery for neurodegenerative diseases (2009) (7)
Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference (2018) (6)
Cost consequences and cost benefits of treating patients with moderate to severe Alzheimer disease (2005) (6)
Comprar Brocklehurst's Textbook Of Geriatric Medicine And Gerontology 8th Ed. | Howard Fillit | 9780702061851 | Elsevier España (2016) (6)
Racial and Ethnic Differences in Hospice Use and Hospitalizations at End-of-Life Among Medicare Beneficiaries With Dementia (2022) (6)
Studies of the cellular immune response to heparan sulfate proteoglycan in the tight skin mouse. (1993) (6)
Using Digital Tools to Advance Alzheimer’s Drug Trials During a Pandemic: The EU/US CTAD Task Force (2021) (6)
Autoimmune MRL mice express high-affinity IgG2b monoclonal autoantibodies to heparin. (1996) (6)
Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery (2013) (6)
Predicting Alzheimer’s disease progression using multi-modal deep learning approach (2019) (6)
An analysis of global research funding for the frontotemporal dementias: 1998–2008 (2011) (6)
Partnerships between philanthropy, government and industry are needed to advance drug discovery for neurodegenerative diseases. (2006) (6)
Interleukin-1 and nerve growth factor induce hypersecretion and hypersulfation of neuroblastoma proteoglycans which bind β-amyloid (1995) (6)
New directions in neuroprotection: basic mechanisms, molecular targets and treatment strategies. (2005) (6)
Vascular dementia: how to make the diagnosis in office practice. (1993) (6)
In vitro correlates of endothelial injury and repair. (1982) (6)
Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil (2010) (5)
A Brief Telephonic Instrument to Screen for Cognitive Impairment in a Managed Care Population (2003) (5)
Economics, pharmacoeconomics and drug discovery for dementias. (2002) (5)
IPECAD5 — Fifth International Pharmaco-Economic Conference on Alzheimer’s Disease (2009) (5)
IPECAD5--Fifth International Pharmaco-Economic Conference on Alzheimer's Disease. (2010) (5)
Methodological challenges in assessing the impact of comorbidities on costs in Alzheimer’s disease clinical trials (2014) (5)
An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease (2022) (5)
Improving Early Recognition of Alzheimer's Disease: A Review of Telephonic Screening Tools (2001) (5)
Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review (2020) (5)
Analysis of Episodes of Care in Medicare Beneficiaries Newly Diagnosed with Alzheimer's Disease (2018) (5)
The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory (2019) (5)
Tau and Alzheimer’s disease (2002) (4)
Tau and Alzheimer's disease: the long road to anti-tangle therapeutics. (2002) (4)
Clinical trials: new opportunities. (2012) (4)
Commentary on “The Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, 2006.” Clinical guidelines are not enough: System-wide, population-based programs are needed to improve the care of patients with Alzheimer’s disease and related dementias (2007) (4)
Meeting report on the Alzheimer’s Drug Discovery Foundation 14th International Conference on Alzheimer’s Drug Discovery (2014) (4)
Vascular dementia: an updated approach to patient management. A roundtable discussion: Part 3. (1994) (4)
Progress in novel cognitive enhancers for cognitive aging and Alzheimer’s disease (2013) (4)
Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology (2020) (3)
Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials (2022) (3)
Tumor necrosis factor-alpha alters the metabolism of endothelial cell proteoglycans. (1994) (3)
Investing in Late-Life Brain Capital (2022) (3)
Glucose metabolism patterns: A potential index to characterize brain ageing and predict high conversion risk into cognitive impairment (2022) (3)
Making geriatric assessment an asset to your primary care practice. (1994) (3)
Comprar Brocklehurst's Textbook of Geriatric Medicine and Gerontology, 7th Edition | Howard Fillit | 9781416062318 | Churchill Livingstone (2010) (3)
Optimizing the use of CROs by academia and small companies (2013) (3)
CHAPTER 1 – Introduction: Aging, Frailty, and Geriatric Medicine (2010) (3)
The Road Ahead To Cure And Prevent Alzheimer's Disease: Implementing Prevention into Primary Care. (2015) (3)
Practical Geriatric Assessment (1998) (2)
A diverse portfolio of novel drug discovery efforts for Alzheimer's disease: Meeting report from the 11th International Conference on Alzheimer's Drug Discovery, 27-28 September 2010, Jersey City, NJ, USA (2010) (2)
Commentary: Global Alzheimer's disease and Alzheimer's disease related dementia research funding organizations support and engage the research community throughout the COVID‐19 pandemic (2021) (2)
PHARMACOLOGIC TREATMENT OF ALZHEIMER'S DISEASE: EFFICACY, DOSING, AND CONTROVERSIES (2007) (2)
The Effects of Rasagiline on Glucose Metabolism and Cognition and Their Relationship to Tau Burden in a Double-Blind, Placebo-Controlled Phase Ii Clinical Trial of Participants with Alzheimer's Dementia (2020) (2)
The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease (2020) (2)
P3-483: Memantine discontinuation in nursing home residents with Alzheimer's disease was associated with an increase in Alzheimer's disease symptoms (2008) (2)
Monoclonal antibody to heparan sulfate from autoimmune tight skin (TSK) mice binds to the endothelial cell surface. (1997) (2)
A multi-targeted approach for a complex multifaceted disease. (2009) (2)
The geriatric evaluation and treatment unit: a model site for acute care of the frail elderly, education, and research. (1993) (2)
Meeting report on the Alzheimer’s Drug Discovery Foundation 14th International Conference on Alzheimer’s Drug Discovery (2014) (1)
Interleukin-1 and nerve growth factor induce hypersecretion and hypersulfation of neuroblastoma proteoglycans which bind beta-amyloid. (1995) (1)
Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil. (2010) (1)
O4-04-01 A hierarchical approach to practical assessment of cognitive decline in the elderly (2006) (1)
Prevention of cognitive dysfunction following surgery: An unmet clinical opportunity (2016) (1)
Letter to the Editor re: Nexus of Cancer & Alzheimer's (2017) (1)
Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” Primary prevention of dementia in Alzheimer's disease: A perspective from prevention research in cardiovascular disease and stroke (2009) (1)
Real-Time Digital Contact Tracing: Development of a System to Control COVID-19 Outbreaks in Nursing Homes and Long-Term Care Facilities (Preprint) (2020) (1)
Acute care of dementia patients: specialized programs needed. (1994) (1)
Heritability of regional brain volumes in large-scale neuroimaging and genetic studies (2017) (1)
Geriatrics and Health Care Reform: Opportunities in Managed Care for Preserving Excellence in the Care of the Elderly (1994) (1)
Frontotemporal Degeneration , the Next Therapeutic Frontier : Molecules and Animal Models for FTD drug development ( Part 1 of 2 articles ) (2013) (1)
Standardizing Electronic Health Record Data on AD/ADRD to Accelerate Health Equity in Prevention, Detection, and Treatment (2022) (1)
Discontinuation of Memantine Therapy in Nursing Home Residents With Alzheimer’s Disease is Associated With Increased Utilization of Psychotropic Medications and Decreased Body Weight (2008) (1)
30-DAY HOSPITAL READMISSIONS AMONG MEDICARE BENEFICIARIES WITH ALZHEIMER’S DISEASE AND RELATED DEMENTIAS PRIOR TO AND FOLLOWING DIAGNOSIS (2016) (1)
Getting More Clinically Meaningful Measures of Functional Impairment for Alzheimer's Disease. (2017) (1)
The Advantages of FTD Drug Development ( Part 2 of FTD : The Next Therapeutic Frontier ) (2013) (1)
SINGLE ENDPOINT FOR NEW DRUG APPROVALS FOR ALZHEIMER ’ S DISEASE (2017) (1)
Reversible acquired immunodeficiency in the elderly: A review (1991) (1)
Sara and George and Justice (2004) (1)
Our Parents, Ourselves: How American Health Care Imperils Middle Age and Beyond (2006) (1)
Distribution of the Iron-Binding Protein Lactoferrin in the Pathological Lesions of Neurodegenerative Diseases (1997) (1)
Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer’s Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers? (2018) (0)
Artificial Intelligence–Powered Digital Health Platform and Wearable Devices Improve Outcomes for Older Adults in Assisted Living Communities: Pilot Intervention Study (Preprint) (2020) (0)
The need for a harmonized speech dataset for Alzheimer’s disease biomarker development (2020) (0)
Alzheimer’s disease medication utilization patterns: Disparities in treatment initiation, non‐adherence, and discontinuation (2021) (0)
Improved screening approach for MCI and dementia in the elderly (2005) (0)
PND6 COST-EFFECTIVENESS OF SCREENING FOR COGNITIVE IMPAIRMENT IN OLDER POPULATIONS: IMPLICATIONS FOR ALZHEIMER'S DISEASE CARE (2007) (0)
Pattern Discovery in Brain Imaging Genetics via SCCA Modeling with a Generic Non-convex Penalty (2017) (0)
Alzheimer Disease: New Drugs in the Offing? (2017) (0)
2016 Antiaging Medicine (2016) (0)
P2-430: The association between use of intravenous immunoglobulin and risk of Alzheimer's disease and related disorders (2008) (0)
Author Correction: Multimodal hippocampal subfield grading for Alzheimer’s disease classification (2020) (0)
Brief Screen for Cognitive Impairment (2018) (0)
The Relevance of Assessing Cognitive Performances in Patients With Cerebrovascular (2016) (0)
Our parents, ourselves . Author's reply (2006) (0)
Alzheimer's disease drug discovery: Abeta and beyond. (2010) (0)
BASELINE FINDINGS FROM GERAS-US: A LONGITUDINAL COHORT STUDY OF RESOURCE USE AND COSTS OF MILD COGNITIVE IMPAIRMENT AND MILD DEMENTIA DUE TO ALZHEIMER’S DISEASE (AD) IN THE UNITED STATES (2018) (0)
Author Correction: Multimodal hippocampal subfield grading for Alzheimer’s disease classification (2020) (0)
The Neurofilament Surveillance Project (NSP): A biomarker study to sample blood quarterly in familial frontotemporal lobar degeneration (2022) (0)
New concepts of glomerular injury. (1984) (0)
Progress in novel cognitive enhancers for cognitive aging and Alzheimer’s disease (2013) (0)
P3-408 Healthcare costs of vascular dementia in community-dwelling patients (2004) (0)
Current and future option sin the treatment of Alzheimer's disease (2003) (0)
Impact of agitation in long‐term care residents with dementia in the United States (2021) (0)
Racial and Ethnic Differences in Hospice Use and End‐of‐life Hospitalizations among Medicare Beneficiaries with Dementia (2022) (0)
An Update on Healthcare Resource Use and Economic Burden In Alzheimer's Disease In The United States (Us) From A Medicare Sample Analysis. (2015) (0)
Practical evaluation of secondary immune deficiencies in the elderly. (1991) (0)
New strategy for alzheimer'S. (2019) (0)
20 Novel programs in drug discovery for Alzheimer's disease (2012) (0)
Chemical Composition of Antigenic Preparations (0)
A NOVEL APPROACH TO STUDY HEALTHCARE RESOURCE USE AND COSTS OF CARE AMONG MEDICARE-ENROLLED PATIENTS DURING AND AFTER PARTICIPATING IN CLINICAL TRIALS FOR EARLY ALZHEIMER'S DISEASE (2019) (0)
Disease progression and costs at the 3‐year follow‐up of the GERAS‐US study (2023) (0)
Perspective Developing novel blood-based biomarkers for Alzheimer's disease (2014) (0)
Serial studies oncirculating immunecomplexes inpost-streptococc al sequelae (1978) (0)
The effects of rasagiline on cerebral glucose metabolism, cognition, and tau in a double-blind, placebo-controlled Phase II clinical trial in Alzheimer’s dementia (2020) (0)
Health Care Utilization and Costs in Treated and Non-Treated Patients Newly Diagnosed with Alzheimer’s Disease in the United States (2016) (0)
Editorial [ Drug Discovery for Alzheimers Disease: Filling the Pipeline Guest Editors: Antony R. Horton and Howard M. Fillit ] (2007) (0)
The relationship of group A streptococci and mammalian tissue antigens to certain disease states. (1979) (0)
DISEASE PROGRESSION AND COSTS AT 1-YEAR FOLLOW-UP OF GERAS-US: A 3-YEAR STUDY OF MILD COGNITIVE IMPAIRMENT AND MILD DEMENTIA DUE TO ALZHEIMER’S DISEASE IN THE UNITED STATES (2019) (0)
PND99 A STUDY OF PREFERENCES FOR DISEASE-MODIFYING TREATMENTS FOR ALZHEIMERâ€™S DISEASE (2020) (0)
End‐of‐life burdensome interventions among Medicare fee‐for‐service beneficiaries with no dementia, non‐advanced dementia, and advanced dementia (2022) (0)
A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline (2016) (0)
The Dawn of a New Era of Alzheimer’s Research and Drug Development (2022) (0)
Alzheimer’s Disease Linkage to Evidence (AD-LINE) Study Early Results: Linking Real-World Claims Data to Phase III GRADUATE Study of Gantenerumab (P7-6.009) (2023) (0)
Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery (2013) (0)
Early Life Matters in Very Late Life (2017) (0)
1st Conference Clinical Trials on Alzheimer’s Disease September 17-18-19, 2008 School of Medecine Montpellier, France (2008) (0)
Recognizing the Spectrum of Cognitive Impairment to Advance Drug Discovery. (2016) (0)
Chronic nephritis after acute poststreptococcal glomerulonephritis. (1978) (0)
The trend of disruption in the functional brain network topology of Alzheimer’s disease (2021) (0)
Disease progression and costs at 3‐year follow‐up of GERAS‐US: A 3‐year study of mild cognitive impairment and mild dementia due to Alzheimer’s disease in the United States (2021) (0)
NOVEL ENVELOPING MECHANISM OF ACTION OF ALZ-801: CONFORMATIONAL STABILIZATION OF BETA AMYLOID BY A SMALL MOLECULE RESULTS IN ANTI-OLIGOMER ACTIVITY (2017) (0)
The economics and pharmacoeconomics of mild cognitive impairment (2005) (0)
Alzheimer's disease medication use and adherence patterns by race and ethnicity (2022) (0)
Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics (2019) (0)
Author Correction: FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease (2022) (0)
EPISODES OF CARE AMONG MEDICARE ELIGIBLE ALZHEIMER’S DISEASE PATIENTS DIAGNOSED IN INPATIENT SETTINGS IN THE UNITED STATES (2017) (0)
COMPARISON OF HEALTHCARE COSTS FOR ALZHEIMER’S DISEASE (AD) PATIENTS DIAGNOSED IN INPATIENT VERSUS NON-INPATIENT SETTINGS (2017) (0)
Systemtic and reg.ional hemodynamic effects of perindopril in exp.erimentaI heart fa.ilure (1993) (0)
P-002 The effect of individual characteristics on benefit-risk trade-offs for modifying the progression of Alzheimer’s disease (2007) (0)
Epigenetics and Alzheimer Risk (2017) (0)
Research activities in the Department of Geriatrics and Adult Development. (1993) (0)
Disease progression and costs at two‐year follow‐up of GERAS‐US: A three‐year study of mild cognitive impairment and mild dementia due to Alzheimer’s disease in the United States (2020) (0)
Satellite Symposium: Emerging Clinical Practices in AA Amyloidosis (2004) (0)
Toward comprehensive value assessment for Alzheimer's disease innovations (2022) (0)
Drug discovery for Alzheimer's disease: filling the pipeline. (2007) (0)
including nonprivatized Medicare, yet never addresses argu- ments underlying my position. (2017) (0)
Deep learning-based polygenic risk analysis for Alzheimer’s disease prediction (2023) (0)
Alzheimer Research Forum live discussion: lost in translation? Charting the course in preclinical therapeutic development. (2006) (0)
TRENDS IN RACIAL AND ETHNIC DIFFERENCES IN DEMENTIA PREVALENCE RATES AND DISEASE AWARENESS (2019) (0)
“Our Parents, Ourselves”—Reply (2006) (0)
Contents, Vol. 39, 1993 (1993) (0)
Senior Health Advisor, Version 1.0 (1996) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Howard M. Fillit?

Howard M. Fillit is affiliated with the following schools: